JP5102928B2 - 新規な葉酸代謝拮抗薬の組み合わせ療法 - Google Patents
新規な葉酸代謝拮抗薬の組み合わせ療法 Download PDFInfo
- Publication number
- JP5102928B2 JP5102928B2 JP2002506715A JP2002506715A JP5102928B2 JP 5102928 B2 JP5102928 B2 JP 5102928B2 JP 2002506715 A JP2002506715 A JP 2002506715A JP 2002506715 A JP2002506715 A JP 2002506715A JP 5102928 B2 JP5102928 B2 JP 5102928B2
- Authority
- JP
- Japan
- Prior art keywords
- vitamin
- administration
- administered
- antifolate
- folic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000004052 folic acid antagonist Substances 0.000 title abstract description 79
- 230000003432 anti-folate effect Effects 0.000 title abstract description 75
- 229940127074 antifolate Drugs 0.000 title abstract description 75
- 239000003814 drug Substances 0.000 title description 57
- 229940079593 drug Drugs 0.000 title description 55
- 238000002648 combination therapy Methods 0.000 title description 2
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 26
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 125
- 239000011724 folic acid Substances 0.000 claims description 70
- 235000019152 folic acid Nutrition 0.000 claims description 70
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 57
- 229960000304 folic acid Drugs 0.000 claims description 57
- 231100000419 toxicity Toxicity 0.000 claims description 27
- 230000001988 toxicity Effects 0.000 claims description 27
- 238000011282 treatment Methods 0.000 claims description 26
- 238000010255 intramuscular injection Methods 0.000 claims description 11
- 239000007927 intramuscular injection Substances 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 10
- 230000000259 anti-tumor effect Effects 0.000 claims description 9
- 230000002829 reductive effect Effects 0.000 claims description 8
- 238000009472 formulation Methods 0.000 claims description 6
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 claims 16
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 claims 11
- ZIYVHBGGAOATLY-UHFFFAOYSA-N methylmalonic acid Chemical compound OC(=O)C(C)C(O)=O ZIYVHBGGAOATLY-UHFFFAOYSA-N 0.000 abstract description 43
- 241000124008 Mammalia Species 0.000 abstract description 22
- 238000000034 method Methods 0.000 abstract description 19
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 49
- 229930003779 Vitamin B12 Natural products 0.000 description 39
- 235000019163 vitamin B12 Nutrition 0.000 description 39
- 239000011715 vitamin B12 Substances 0.000 description 39
- WBXPDJSOTKVWSJ-ZDUSSCGKSA-N pemetrexed Chemical compound C=1NC=2NC(N)=NC(=O)C=2C=1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 WBXPDJSOTKVWSJ-ZDUSSCGKSA-N 0.000 description 32
- 229940110282 alimta Drugs 0.000 description 31
- 239000011230 binding agent Substances 0.000 description 17
- 230000004614 tumor growth Effects 0.000 description 17
- 206010028980 Neoplasm Diseases 0.000 description 15
- 241001465754 Metazoa Species 0.000 description 12
- 229940014144 folate Drugs 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 230000000340 anti-metabolite Effects 0.000 description 10
- 229940100197 antimetabolite Drugs 0.000 description 10
- 239000002256 antimetabolite Substances 0.000 description 10
- 208000010201 Exanthema Diseases 0.000 description 9
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 9
- 201000005884 exanthem Diseases 0.000 description 9
- 206010037844 rash Diseases 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 8
- 231100000331 toxic Toxicity 0.000 description 8
- 230000002588 toxic effect Effects 0.000 description 8
- 229940088594 vitamin Drugs 0.000 description 8
- 229930003231 vitamin Natural products 0.000 description 8
- 235000013343 vitamin Nutrition 0.000 description 8
- 239000011782 vitamin Substances 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 208000012766 Growth delay Diseases 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 108010022394 Threonine synthase Proteins 0.000 description 7
- 230000034994 death Effects 0.000 description 7
- 231100000517 death Toxicity 0.000 description 7
- 150000003722 vitamin derivatives Chemical class 0.000 description 7
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 6
- 206010006187 Breast cancer Diseases 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 231100000046 skin rash Toxicity 0.000 description 6
- 208000026310 Breast neoplasm Diseases 0.000 description 5
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 235000005911 diet Nutrition 0.000 description 5
- 102000004419 dihydrofolate reductase Human genes 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 229960000485 methotrexate Drugs 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 210000002700 urine Anatomy 0.000 description 5
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 4
- 229960004316 cisplatin Drugs 0.000 description 4
- 230000001472 cytotoxic effect Effects 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 4
- ZUQBAQVRAURMCL-DOMZBBRYSA-N (2s)-2-[[4-[2-[(6r)-2-amino-4-oxo-5,6,7,8-tetrahydro-1h-pyrido[2,3-d]pyrimidin-6-yl]ethyl]benzoyl]amino]pentanedioic acid Chemical compound C([C@@H]1CC=2C(=O)N=C(NC=2NC1)N)CC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 ZUQBAQVRAURMCL-DOMZBBRYSA-N 0.000 description 3
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 3
- 101000606741 Homo sapiens Phosphoribosylglycinamide formyltransferase Proteins 0.000 description 3
- 206010028116 Mucosal inflammation Diseases 0.000 description 3
- 201000010927 Mucositis Diseases 0.000 description 3
- 241000699660 Mus musculus Species 0.000 description 3
- 206010033733 Papule Diseases 0.000 description 3
- 102100039654 Phosphoribosylglycinamide formyltransferase Human genes 0.000 description 3
- 101001039269 Rattus norvegicus Glycine N-methyltransferase Proteins 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003651 drinking water Substances 0.000 description 3
- 235000020188 drinking water Nutrition 0.000 description 3
- 229960002949 fluorouracil Drugs 0.000 description 3
- 125000003929 folic acid group Chemical group 0.000 description 3
- 230000002489 hematologic effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 229950000909 lometrexol Drugs 0.000 description 3
- 208000004235 neutropenia Diseases 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 238000011580 nude mouse model Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- 230000009469 supplementation Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 206010043554 thrombocytopenia Diseases 0.000 description 3
- 230000002485 urinary effect Effects 0.000 description 3
- 208000002670 vitamin B12 deficiency Diseases 0.000 description 3
- 230000004580 weight loss Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 102100024746 Dihydrofolate reductase Human genes 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 102000005497 Thymidylate Synthase Human genes 0.000 description 2
- IVTVGDXNLFLDRM-HNNXBMFYSA-N Tomudex Chemical compound C=1C=C2NC(C)=NC(=O)C2=CC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)S1 IVTVGDXNLFLDRM-HNNXBMFYSA-N 0.000 description 2
- 206010070863 Toxicity to various agents Diseases 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- 201000008275 breast carcinoma Diseases 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 238000009104 chemotherapy regimen Methods 0.000 description 2
- BYLXFSREGROOBJ-UVKKECPRSA-K cobalt(3+) [(2R,3S,4R,5S)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2R)-1-[3-[(2R,3R,4Z,7S,9Z,12S,13S,14Z,17S,18S,19R)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7,12,17-tetrahydro-1H-corrin-21-id-3-yl]propanoylamino]propan-2-yl] phosphate chloride Chemical compound [Cl-].[Co+3].C[C@H](CNC(=O)CC[C@]1(C)[C@@H](CC(N)=O)C2[N-]\C1=C(C)/C1=N/C(=C\C3=N\C(=C(C)/C4=N[C@]2(C)[C@@](C)(CC(N)=O)[C@@H]4CCC(N)=O)\[C@@](C)(CC(N)=O)[C@@H]3CCC(N)=O)/C(C)(C)[C@@H]1CCC(N)=O)OP([O-])(=O)O[C@@H]1[C@@H](CO)O[C@@H]([C@@H]1O)n1cnc2cc(C)c(C)cc12 BYLXFSREGROOBJ-UVKKECPRSA-K 0.000 description 2
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 108020001096 dihydrofolate reductase Proteins 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 230000009760 functional impairment Effects 0.000 description 2
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 2
- 231100000226 haematotoxicity Toxicity 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 231100001225 mammalian toxicity Toxicity 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 239000003944 phosphoribosylglycinamide formyltransferase inhibitor Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 2
- 229960004432 raltitrexed Drugs 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 231100000004 severe toxicity Toxicity 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical class OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- 239000003734 thymidylate synthase inhibitor Substances 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 235000019158 vitamin B6 Nutrition 0.000 description 2
- 239000011726 vitamin B6 Substances 0.000 description 2
- 229940082632 vitamin b12 and folic acid Drugs 0.000 description 2
- 229940011671 vitamin b6 Drugs 0.000 description 2
- 235000019195 vitamin supplement Nutrition 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- VVIAGPKUTFNRDU-OLZOCXBDSA-N (2s)-2-[[4-[[(6r)-2-amino-5-formyl-4-oxo-1,6,7,8-tetrahydropteridin-6-yl]methylamino]benzoyl]amino]pentanedioic acid Chemical compound C([C@H]1N(C=O)C=2C(=O)N=C(NC=2NC1)N)NC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-OLZOCXBDSA-N 0.000 description 1
- ZNOVTXRBGFNYRX-OLZOCXBDSA-N (2s)-2-[[4-[[(6r)-2-amino-5-methyl-4-oxo-1,6,7,8-tetrahydropteridin-6-yl]methylamino]benzoyl]amino]pentanedioic acid Chemical compound C([C@H]1N(C=2C(=O)NC(N)=NC=2NC1)C)NC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 ZNOVTXRBGFNYRX-OLZOCXBDSA-N 0.000 description 1
- MSTNYGQPCMXVAQ-RYUDHWBXSA-N (6S)-5,6,7,8-tetrahydrofolic acid Chemical class C([C@H]1CNC=2N=C(NC(=O)C=2N1)N)NC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 MSTNYGQPCMXVAQ-RYUDHWBXSA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- KDOPAZIWBAHVJB-UHFFFAOYSA-N 5h-pyrrolo[3,2-d]pyrimidine Chemical compound C1=NC=C2NC=CC2=N1 KDOPAZIWBAHVJB-UHFFFAOYSA-N 0.000 description 1
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 1
- JJTNLWSCFYERCK-UHFFFAOYSA-N 7h-pyrrolo[2,3-d]pyrimidine Chemical compound N1=CN=C2NC=CC2=C1 JJTNLWSCFYERCK-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 206010052358 Colorectal cancer metastatic Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- 208000030814 Eating disease Diseases 0.000 description 1
- 208000019454 Feeding and Eating disease Diseases 0.000 description 1
- 206010016880 Folate deficiency Diseases 0.000 description 1
- 206010059024 Gastrointestinal toxicity Diseases 0.000 description 1
- OBQMLSFOUZUIOB-UHFFFAOYSA-N Glycinamide ribonucleotide Natural products NCC(=O)NC1OC(COP(O)(O)=O)C(O)C1O OBQMLSFOUZUIOB-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010037898 Rash vesicular Diseases 0.000 description 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- KVUAALJSMIVURS-ZEDZUCNESA-L calcium folinate Chemical compound [Ca+2].C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 KVUAALJSMIVURS-ZEDZUCNESA-L 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 235000019365 chlortetracycline Nutrition 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 235000000639 cyanocobalamin Nutrition 0.000 description 1
- 239000011666 cyanocobalamin Substances 0.000 description 1
- 229960002104 cyanocobalamin Drugs 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- NYDXNILOWQXUOF-UHFFFAOYSA-L disodium;2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioate Chemical class [Na+].[Na+].C=1NC=2NC(N)=NC(=O)C=2C=1CCC1=CC=C(C(=O)NC(CCC([O-])=O)C([O-])=O)C=C1 NYDXNILOWQXUOF-UHFFFAOYSA-L 0.000 description 1
- 235000014632 disordered eating Nutrition 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002875 fluorescence polarization Methods 0.000 description 1
- 102000036215 folic acid binding proteins Human genes 0.000 description 1
- 108091011001 folic acid binding proteins Proteins 0.000 description 1
- 235000008191 folinic acid Nutrition 0.000 description 1
- 239000011672 folinic acid Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 231100000414 gastrointestinal toxicity Toxicity 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 1
- 238000013415 human tumor xenograft model Methods 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 229960001691 leucovorin Drugs 0.000 description 1
- 231100001106 life-threatening toxicity Toxicity 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000010197 meta-analysis Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 208000022084 motor paralysis Diseases 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 229960005079 pemetrexed Drugs 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 159000000018 pyrido[2,3-d]pyrimidines Chemical class 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000011916 stereoselective reduction Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Detergent Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21531000P | 2000-06-30 | 2000-06-30 | |
| US60/215,310 | 2000-06-30 | ||
| US23585900P | 2000-09-27 | 2000-09-27 | |
| US60/235,859 | 2000-09-27 | ||
| US28444801P | 2001-04-18 | 2001-04-18 | |
| US60/284,448 | 2001-04-18 | ||
| PCT/US2001/014860 WO2002002093A2 (en) | 2000-06-30 | 2001-06-15 | Combination containing an antifolate and methylmalonic acid lowering agent |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012144570A Division JP5469706B2 (ja) | 2000-06-30 | 2012-06-27 | 新規な葉酸代謝拮抗薬の組み合わせ療法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004501964A JP2004501964A (ja) | 2004-01-22 |
| JP2004501964A5 JP2004501964A5 (enExample) | 2008-11-20 |
| JP5102928B2 true JP5102928B2 (ja) | 2012-12-19 |
Family
ID=27396105
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002506715A Expired - Lifetime JP5102928B2 (ja) | 2000-06-30 | 2001-06-15 | 新規な葉酸代謝拮抗薬の組み合わせ療法 |
| JP2012144570A Expired - Lifetime JP5469706B2 (ja) | 2000-06-30 | 2012-06-27 | 新規な葉酸代謝拮抗薬の組み合わせ療法 |
| JP2013213276A Withdrawn JP2014005304A (ja) | 2000-06-30 | 2013-10-11 | 新規な葉酸代謝拮抗薬の組み合わせ療法 |
| JP2015087012A Withdrawn JP2015178501A (ja) | 2000-06-30 | 2015-04-21 | 新規な葉酸代謝拮抗薬の組み合わせ療法 |
| JP2016192173A Withdrawn JP2017019852A (ja) | 2000-06-30 | 2016-09-29 | 新規な葉酸代謝拮抗薬の組み合わせ療法 |
| JP2018156677A Withdrawn JP2018197265A (ja) | 2000-06-30 | 2018-08-23 | 新規な葉酸代謝拮抗薬の組み合わせ療法 |
| JP2020072098A Pending JP2020117536A (ja) | 2000-06-30 | 2020-04-14 | 新規な葉酸代謝拮抗薬の組み合わせ療法 |
Family Applications After (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012144570A Expired - Lifetime JP5469706B2 (ja) | 2000-06-30 | 2012-06-27 | 新規な葉酸代謝拮抗薬の組み合わせ療法 |
| JP2013213276A Withdrawn JP2014005304A (ja) | 2000-06-30 | 2013-10-11 | 新規な葉酸代謝拮抗薬の組み合わせ療法 |
| JP2015087012A Withdrawn JP2015178501A (ja) | 2000-06-30 | 2015-04-21 | 新規な葉酸代謝拮抗薬の組み合わせ療法 |
| JP2016192173A Withdrawn JP2017019852A (ja) | 2000-06-30 | 2016-09-29 | 新規な葉酸代謝拮抗薬の組み合わせ療法 |
| JP2018156677A Withdrawn JP2018197265A (ja) | 2000-06-30 | 2018-08-23 | 新規な葉酸代謝拮抗薬の組み合わせ療法 |
| JP2020072098A Pending JP2020117536A (ja) | 2000-06-30 | 2020-04-14 | 新規な葉酸代謝拮抗薬の組み合わせ療法 |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US7053065B2 (enExample) |
| EP (1) | EP1313508B1 (enExample) |
| JP (7) | JP5102928B2 (enExample) |
| AT (1) | ATE359823T1 (enExample) |
| AU (1) | AU2001269688A1 (enExample) |
| CY (1) | CY1107649T1 (enExample) |
| DE (1) | DE60127970T2 (enExample) |
| DK (1) | DK1313508T5 (enExample) |
| ES (1) | ES2284660T3 (enExample) |
| PT (1) | PT1313508E (enExample) |
| WO (1) | WO2002002093A2 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7053065B2 (en) * | 2000-06-30 | 2006-05-30 | Eli Lilly And Company | Vitamin B12 and pemetrexed disodium combination therapies |
| ES2417065T3 (es) | 2005-04-26 | 2013-08-05 | Trion Pharma Gmbh | Combinación de anticuerpos con glucocorticoides para el tratamiento del cáncer |
| BRPI0706528A2 (pt) * | 2006-01-12 | 2011-03-29 | Novartis Ag | combinação de inibidor de mtor e composto antifolato |
| WO2010021843A1 (en) * | 2008-08-20 | 2010-02-25 | Eli Lilly And Company | Use of antifolates in patients with detectable levels of tff-1 for the cancer treatment |
| WO2010138955A2 (en) | 2009-05-29 | 2010-12-02 | University Of Florida Research Foundation, Inc. | Methods and compositions for treating neoplasia |
| US10736969B2 (en) | 2010-12-21 | 2020-08-11 | Nektar Therapeutics | Multi-arm polymeric prodrug conjugates of pemetrexed-based compounds |
| WO2013179248A1 (en) | 2012-05-30 | 2013-12-05 | Fresenius Kabi Oncology Ltd. | Pharmaceutical compositions of pemetrexed |
| AU2015268962A1 (en) * | 2014-06-04 | 2017-01-12 | Thomas Helledays Stiftelse For Medicinsk Forskning | MTH1 inhibitors for treatment of inflammatory and autoimmune conditions |
| CA2986702C (en) | 2015-05-21 | 2023-04-04 | David Wang | Modified demineralized cortical bone fibers |
| US9746477B2 (en) * | 2015-07-30 | 2017-08-29 | Expression Pathology, Inc. | Quantifying FR-α and GART proteins for optimal cancer therapy |
| IL259512B2 (en) * | 2015-12-07 | 2024-03-01 | General Oncology Inc | Combination for the effective treatment of metastatic cancer in patients |
| WO2018031968A1 (en) | 2016-08-12 | 2018-02-15 | L.E.A.F. Holdings Group Llc | Alpha and gamma-d polyglutamated antifolates and uses thereof |
| CA3033083A1 (en) | 2016-08-12 | 2018-02-15 | L.E.A.F. Holdings Group Llc | Polyglutamated antifolates and uses thereof |
| US11584733B2 (en) | 2017-01-09 | 2023-02-21 | Shuttle Pharmaceuticals, Inc. | Selective histone deacetylase inhibitors for the treatment of human disease |
| CA3049435A1 (en) | 2017-01-09 | 2018-07-12 | Scott Grindrod | Selective histone deacetylase inhibitors for the treatment of human disease |
| EP3737376B1 (en) | 2018-01-09 | 2024-04-17 | Shuttle Pharmaceuticals, Inc. | Selective histone deacetylase inhibitors for the treatment of human diseases |
| US12220431B2 (en) | 2018-02-07 | 2025-02-11 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated antifolates and uses thereof |
| EP3749312A4 (en) | 2018-02-07 | 2022-02-23 | L.E.A.F Holdings Group LLC | ALPHA-POLYGLUTAMATED LOMETREXOLE AND USES THEREOF |
| CA3090500A1 (en) | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated antifolates and uses thereof |
| EP3749317A4 (en) | 2018-02-07 | 2022-06-22 | L.E.A.F Holdings Group LLC | PEMETREXED ALPHA-POLYGLUTAMATE AND ASSOCIATED USES |
| WO2019157123A1 (en) | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated aminopterin and uses thereof |
| EP3749314A4 (en) | 2018-02-07 | 2022-02-23 | L.E.A.F Holdings Group LLC | ALPHA-POLYGLUTAMATE METHOTREXATE AND ITS USES |
| US12246015B2 (en) | 2018-02-07 | 2025-03-11 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated raltitrexed and uses thereof |
| EP3749316A4 (en) | 2018-02-07 | 2021-10-27 | L.E.A.F Holdings Group LLC | ALPHA-POLYGLUTAMATED PRALATREXATE AND USES THEREOF |
| WO2019157140A1 (en) | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated raltitrexed and uses thereof |
| EP3749319A4 (en) | 2018-02-07 | 2022-06-22 | L.E.A.F Holdings Group LLC | TETRAHYDROFOLATES ALPHA POLYGLUTAMATE AND THEIR USES |
| EP3749311A4 (en) | 2018-02-07 | 2022-07-06 | L.E.A.F Holdings Group LLC | PEMETREXED POLYGLUTAMATE GAMMA COMPOSITIONS AND THEIR USES |
| CN111971047A (zh) | 2018-02-14 | 2020-11-20 | L.E.A.F.控股集团公司 | γ聚谷氨酸化四氢叶酸及其用途 |
| JP7462950B2 (ja) | 2018-02-14 | 2024-04-08 | エル．イー．エー．エフ． ホールディングス グループ エルエルシー | ガンマポリグルタミン酸化メトトレキセートおよびその使用 |
| US12048767B2 (en) | 2018-02-14 | 2024-07-30 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated pralatrexate and uses thereof |
| CA3090875A1 (en) | 2018-02-14 | 2019-08-22 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated lometrexol and uses thereof |
| CA3090943A1 (en) | 2018-02-14 | 2019-08-22 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated aminopterin and uses thereof |
| WO2023177894A1 (en) | 2022-03-18 | 2023-09-21 | Ideaya Biosciences, Inc. | Combination therapy comprising a mat2a inhibitor and an antimetabolite agent |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US225030A (en) * | 1880-03-02 | Rotary engine | ||
| US216350A (en) * | 1879-06-10 | Improvement in car-replacers | ||
| US2920015A (en) * | 1957-08-27 | 1960-01-05 | Armour & Co | Long-acting vitamin b12 |
| CH588505A5 (enExample) * | 1972-06-08 | 1977-06-15 | Research Corp | |
| US5563126A (en) | 1986-11-20 | 1996-10-08 | Metabolite Laboratories | Method for treatment and prevention of deficiencies of vitamins B12, folic acid, and B6 |
| JP2962755B2 (ja) * | 1989-02-28 | 1999-10-12 | 帝人株式会社 | 新規ビタミンｂ▲下１▼▲下２▼誘導体、その製造方法並びにその用途 |
| US5405839A (en) | 1989-02-28 | 1995-04-11 | Teijin Limited | Vitamin B12 derivative, preparation process thereof, and use thereof |
| KR0162654B1 (ko) * | 1989-12-11 | 1998-11-16 | 알렌 제이. 시니스갤리 | N-(피롤로[2,3-d]피리미딘-3-일아크릴)-글루타민산 유도체 |
| ES2077808T5 (es) * | 1991-03-29 | 2002-10-16 | Lilly Co Eli | Procedimiento terapeutico mejorado. |
| JPH05163160A (ja) * | 1991-12-13 | 1993-06-29 | Snow Brand Milk Prod Co Ltd | 免疫低下に伴う感染症の予防及び治療用栄養剤 |
| US6207651B1 (en) | 1996-08-02 | 2001-03-27 | Metabolite Laboratories | Method for treatment and prevention of deficiencies of vitamins B12, folic acid, and B6 |
| WO1995027723A1 (en) | 1994-04-08 | 1995-10-19 | Receptagen Corporation | Receptor modulating agents and methods relating thereto |
| WO1996012181A1 (en) | 1994-10-12 | 1996-04-25 | Research & Diagnostics Systems, Inc. | Reticulocyte assay control |
| US7053065B2 (en) * | 2000-06-30 | 2006-05-30 | Eli Lilly And Company | Vitamin B12 and pemetrexed disodium combination therapies |
| US20040005311A1 (en) * | 2001-07-20 | 2004-01-08 | Pitman Bradford D. | Dietary supplement compositions |
-
2001
- 2001-06-15 US US10/297,821 patent/US7053065B2/en not_active Expired - Lifetime
- 2001-06-15 WO PCT/US2001/014860 patent/WO2002002093A2/en not_active Ceased
- 2001-06-15 ES ES01948214T patent/ES2284660T3/es not_active Expired - Lifetime
- 2001-06-15 AT AT01948214T patent/ATE359823T1/de active
- 2001-06-15 JP JP2002506715A patent/JP5102928B2/ja not_active Expired - Lifetime
- 2001-06-15 EP EP01948214A patent/EP1313508B1/en not_active Expired - Lifetime
- 2001-06-15 PT PT01948214T patent/PT1313508E/pt unknown
- 2001-06-15 DE DE60127970T patent/DE60127970T2/de not_active Expired - Lifetime
- 2001-06-15 DK DK01948214.0T patent/DK1313508T5/da active
- 2001-06-15 AU AU2001269688A patent/AU2001269688A1/en not_active Abandoned
-
2005
- 2005-11-29 US US11/288,807 patent/US20060079480A1/en not_active Abandoned
-
2007
- 2007-06-07 CY CY20071100756T patent/CY1107649T1/el unknown
- 2007-07-11 US US11/776,329 patent/US7772209B2/en not_active Expired - Fee Related
-
2010
- 2010-04-28 US US12/768,920 patent/US20100210583A1/en not_active Abandoned
-
2012
- 2012-06-27 JP JP2012144570A patent/JP5469706B2/ja not_active Expired - Lifetime
-
2013
- 2013-10-11 JP JP2013213276A patent/JP2014005304A/ja not_active Withdrawn
-
2015
- 2015-04-21 JP JP2015087012A patent/JP2015178501A/ja not_active Withdrawn
-
2016
- 2016-09-29 JP JP2016192173A patent/JP2017019852A/ja not_active Withdrawn
-
2018
- 2018-08-23 JP JP2018156677A patent/JP2018197265A/ja not_active Withdrawn
-
2020
- 2020-04-14 JP JP2020072098A patent/JP2020117536A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20080032948A1 (en) | 2008-02-07 |
| WO2002002093A3 (en) | 2003-02-06 |
| DE60127970T2 (de) | 2007-12-20 |
| AU2001269688A1 (en) | 2002-01-14 |
| ES2284660T3 (es) | 2007-11-16 |
| US7772209B2 (en) | 2010-08-10 |
| US20030212038A1 (en) | 2003-11-13 |
| WO2002002093A2 (en) | 2002-01-10 |
| US20060079480A1 (en) | 2006-04-13 |
| JP2020117536A (ja) | 2020-08-06 |
| JP2012180381A (ja) | 2012-09-20 |
| JP2015178501A (ja) | 2015-10-08 |
| EP1313508B1 (en) | 2007-04-18 |
| JP2018197265A (ja) | 2018-12-13 |
| JP2017019852A (ja) | 2017-01-26 |
| JP2014005304A (ja) | 2014-01-16 |
| US7053065B2 (en) | 2006-05-30 |
| US20100210583A1 (en) | 2010-08-19 |
| DK1313508T5 (da) | 2017-03-20 |
| PT1313508E (pt) | 2007-06-21 |
| EP1313508A2 (en) | 2003-05-28 |
| DK1313508T3 (da) | 2007-08-06 |
| ATE359823T1 (de) | 2007-05-15 |
| JP2004501964A (ja) | 2004-01-22 |
| CY1107649T1 (el) | 2013-04-18 |
| DE60127970D1 (de) | 2007-05-31 |
| JP5469706B2 (ja) | 2014-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5469706B2 (ja) | 新規な葉酸代謝拮抗薬の組み合わせ療法 | |
| van den Bogaert et al. | Pemetrexed maintenance therapy in patients with malignant pleural mesothelioma | |
| CA2450777C (en) | Use of c-src inhibitors alone or in combination with sti571 for the treatment of leukaemia | |
| Archie Bleyer | New vistas for leucovorin in cancer chemotherapy | |
| US5639787A (en) | Therapeutic method for the treatment of cancer | |
| JP2002528507A (ja) | 神経疾患および病態心理学的疾患の治療および予防用の組成物 | |
| US20100008923A1 (en) | Organic Compounds | |
| TWI233359B (en) | Pharmaceutical composition for treating neoplasm | |
| Roberts et al. | Weekly lometrexol with daily oral folic acid is appropriate for phase II evaluation | |
| Conti et al. | Trial of sequential trimetrexate, fluorouracil, and high-dose leucovorin in previously treated patients with gastrointestinal carcinoma. | |
| NZ551082A (en) | Treatment of T-cell lymphoma using 10-propargyl-10-deazaaminopterin | |
| TW201717926A (zh) | 用於治療尤文氏家族腫瘤(ewing family tumors)的組成物及方法 | |
| Llombart-Cussac et al. | Pemetrexed in patients with locally advanced or metastatic breast cancer who had received previous anthracycline and taxane treatment: phase II study | |
| CN1330308C (zh) | 含有4－吡啶基甲基酞嗪的联合产品及其应用 | |
| CA2672716A1 (fr) | Nouvelle utilisation therapeutique pour le traitement des leucemies | |
| Lennard et al. | The effect of folate supplements on 6-mercaptopurine remission maintenance therapy in childhood leukaemia | |
| DE DK et al. | ZUSAMMENSETZUNG, WELCHE EIN ANTIFOLATE UND EIN METHYLMALONSÄURESENKENDES MITTEL ENTHÄLT COMPOSITION COMPRENANT UN ANTIFOLATE ET UN AGENT REDUCTEUR D’ACIDE METHYLMALONIQUE | |
| Nobile et al. | Phase II study with high-dose N5–10-methyltetrahydrofolate and 5-fluorouracil in advanced colorectal cancer | |
| EP0505640B2 (en) | Improved therapeutic method | |
| Celio et al. | Pemetrexed in gastric cancer: clinical experience and future perspectives | |
| JPH07258088A (ja) | Ｇａｒ−トランスホルミラーゼ−依存性腫瘍の治療方法 | |
| HK1146804A (en) | Use of c-src inhibitors alone or in combination with sti571 for the treatment of leukaemia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080522 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20081002 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20090917 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110329 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110629 |
|
| RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20110705 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20110705 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110830 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20120228 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120627 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20120822 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120918 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20121001 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20151005 Year of fee payment: 3 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 Ref document number: 5102928 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| EXPY | Cancellation because of completion of term |